

## Topical Collection

# Vaccines against Infectious Diseases

### Message from the Collection Editor

We are launching a special issue on vaccines against infectious disease, in which we propose to cover aspects of vaccine design, development, formulation, clinical trial and deployment. Despite advances in global healthcare, there is still a clear need for more vaccines against infectious disease, underlined in the past year or more by the coronavirus pandemic. In this series, we will invite a broad range of papers to cover the following topics:

- Vaccines to counter anti-microbial resistance
- Vaccines to eradicate endemic disease-opportunities and challenges
- Vaccines to prevent zoonotic transmission-targeting the animal reservoir
- Vaccine platforms-advantages and disadvantages
- Clinical trial design for reactive and preventive vaccination
- Vaccine deployment in outbreak settings-lessons learned
- Advances in vaccine formulation and adjuvantisation
- WHO pre-qualification of vaccines-creating a Target Product Profile
- Clinical view on routinisation of vaccines
- How do we prepare for vaccines against the as yet unknown?

---

### Collection Editor

Dr. E.Diane Williamson

Defence Science & Technology Laboratory, Porton Down, Salisbury, Wilts SP4 0JQ, UK

---



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 8.9  
Indexed in PubMed



[mdpi.com/si/83699](https://mdpi.com/si/83699)

*Vaccines*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 8.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).